Cellumed Sees Strong Sales of 'Rafugen Dental'... Revenue Growth Accelerates as Dental Market Lead Expands

Cellumed, a subsidiary of InskoBi Group specializing in the manufacturing of bio-medical devices, announced on the 26th that its dental bone graft material, 'Rafugen Dental,' continues to see strong sales in major domestic markets. The company expects this trend to drive significant revenue growth going forward.

'Rafugen Dental' is a high-performance bone graft material used to reconstruct bone defects during implant surgeries. It has earned strong trust from dental professionals due to its excellent biocompatibility and bone regeneration capabilities. As demand for implants increases with an aging population, there has been ongoing positive feedback and requests for expanded supply of the product, particularly in Seoul and the greater metropolitan area.

Earlier this year, Cellumed improved its production processes, increasing its production capacity (CAPA) by up to two times. The company has also recently expanded its global supply chain for raw materials, establishing a stable production system that enables rapid response to rising demand. According to the company, the current surge in demand for 'Rafugen Dental' in medical settings is driving a sharp increase in the facility utilization rate.

The growth of the domestic implant market is also reflected in relevant statistics. According to healthcare big data from the Health Insurance Review and Assessment Service, the number of implant surgery patients in Korea increased by approximately 16%, from 719,309 in 2020 to 837,634 in 2023. This growth is attributed to both the aging population and heightened public interest in oral health, which are having a positive impact on the overall dental graft market.

A Cellumed representative stated, "We are pursuing aggressive marketing strategies to make the dental sector a core strategic business for the company, centered on 'Rafugen Dental.'" The representative added, "We will focus on expanding our market share by diversifying our sales channels based on a stable supply system and technological expertise, as well as developing new products with enhanced efficacy."